News

inVentiv Clinical Trial Recruitment Solutions and the Alliance for Clinical Research Excellence and Safety are partnering toward the development of a global system

Key to accelerating the discovery and development of new medical therapies is to improve the clinical research process.

Further discussion required on wording and practical arrangements

EFPIA criticized the intent of the French government to broadly enlarge the use of off-label drugs for economic reasons, even if there is an approved drug available.

The French government's intention to broadly enlarge the use of off-label drugs for economic reasons is wrong, according to a statement issued by EFPIA

he Lithuanian Ministry of Health and EFPIA, the European Federation of Pharmaceutical Industries and Associations announced a significant new Joint Working Agreement that paves the way for protecting future health and growth in Lithuanian.

inVentiv's Otis Johnson Joins Site Optics and Quality Informatics Steering Committee for Development of Industry Wide Site-Based Performance Metrics and Informatics Standards

ACRP and ENACCT announced the integration of key ENACCT products and services into the current ACRP professional development portfolio.

Scalable Cloud-Based Solution Provides High Availability and IT Cost Predictability

The pharmaceutical industry continues to outsource more clinical trials to contract research organizations each year...

With the help of Oracle Health Sciences Consulting, Santen migrated its legacy data and rolled out the Oracle Argus Cloud Service solution in 10 months.

The European Union has managed to snatch defeat from the jaws of opportunity once more!

Functional service provider arrangements, or FSPs, are evolving beyond the clinical data management tasks they were designed to streamline.

In the clinical development setting, most organizations are already working in an electronic world but still thinking in "paper."

Health technology assessment is a field of analysis that evaluates the medical, social, ethical, and economic implications of development, diffusion, and use of health technology.

The costs of drug development are increasing, driven in large part by increasing failure rates in all phases of clinical development.

Eurofins Central Laboratory is pleased to announce that is has achieved an important strategic milestone with the expansion and relocation of its US Central Laboratory Operations

Eurofins Central Laboratory announced the expansion and relocation of its US Central Laboratory Operations to the company's Pharma Services campus in Lancaster, PA.

Principal Investigators announced global availability of its online platform designed specifically to connect Medical Doctors with Pharma and R&D companies involved in clinical studies

The New and Easier Way to Find Patients and Begin Clinical Trials.

PAREXEL announced today that the Company has acquired all of the outstanding equity securities of ATLAS Medical Services

With the public release of physician payment data slated for September, the implications for medical and scientific communications are many.

PAREXEL announced it has acquired all of the outstanding equity securities of ATLAS Medical Services.

Is the FDA doing enough to incorporate the patient perspective in the drug review process?

AVERT Delivers Proven and Efficient Solution for Broad Assessment of Suicide Risk

The State of Oklahoma, Department of Mental Health and Substance Abuse Services will be implementing ERT's AVERT Suicide Risk Assessment

The mounting outrage over exorbitant prices for new medicines increases the importance of reducing the cost of biomedical product development.

An article that sets the stage for why improvements in the contract negotiations with sites has and needed to improve for the past two years.